All News about Mural Oncology plc - Ordinary Shares
![](https://ml.globenewswire.com/media/d9e29204-8a31-4e27-94d0-027c4d49242a/small/mural-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/d9e29204-8a31-4e27-94d0-027c4d49242a/small/mural-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/d9e29204-8a31-4e27-94d0-027c4d49242a/small/mural-logo-jpg.jpg)
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
![](https://ml.globenewswire.com/media/d9e29204-8a31-4e27-94d0-027c4d49242a/small/mural-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/d9e29204-8a31-4e27-94d0-027c4d49242a/small/mural-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/d9e29204-8a31-4e27-94d0-027c4d49242a/small/mural-logo-jpg.jpg)
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
![](https://ml.globenewswire.com/media/d9e29204-8a31-4e27-94d0-027c4d49242a/small/mural-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/d9e29204-8a31-4e27-94d0-027c4d49242a/small/mural-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/d9e29204-8a31-4e27-94d0-027c4d49242a/small/mural-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/d9e29204-8a31-4e27-94d0-027c4d49242a/small/mural-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/d9e29204-8a31-4e27-94d0-027c4d49242a/small/mural-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/d9e29204-8a31-4e27-94d0-027c4d49242a/small/mural-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/d9e29204-8a31-4e27-94d0-027c4d49242a/small/mural-logo-jpg.jpg)
From Mural Oncology, Inc.
Via GlobeNewswire
![](https://ml.globenewswire.com/media/d9e29204-8a31-4e27-94d0-027c4d49242a/small/mural-logo-jpg.jpg)
From Mural Oncology, Inc.
Via GlobeNewswire
![](https://investorplace.com/wp-content/uploads/2021/11/shutterstock_1667119063.png)
![](https://investorplace.com/wp-content/uploads/2022/10/droplet-test-tube-biotech-1600-3.jpg)
![](https://ml.globenewswire.com/media/d9e29204-8a31-4e27-94d0-027c4d49242a/small/mural-logo-jpg.jpg)
Mural Oncology Announces Enhancements to Late-Stage Clinical Trials
January 08, 2024
From Mural Oncology, Inc.
Via GlobeNewswire
![](https://cdn.benzinga.com/files/images/story/2023/11/20/image23.jpeg?width=1200&height=800&fit=crop)
![](https://investorplace.com/wp-content/uploads/2021/05/wall-street-morning.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/11/17/dolby_laboratories_-_logo.jpg?width=1200&height=800&fit=crop)
![](https://investorplace.com/wp-content/uploads/2022/01/shutterstock_2018142317.png)
![](https://investorplace.com/wp-content/uploads/2021/04/chpt-stock-2.jpg)
![](https://investorplace.com/wp-content/uploads/2022/05/mpw_medicalpropertiestrust1600.png)
![](https://cdn.benzinga.com/files/images/story/2023/11/17/gap2_-_logo.jpg?width=1200&height=800&fit=crop)
![](https://investorplace.com/wp-content/uploads/2021/08/srne_doctor_oncology_1600.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.